We’re thrilled to welcome Richard to our board,” said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. “Richard has a proven track record in the biotechnology sector ...

Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...

Corvus Pharmaceuticals highlighted significant progress for soquelitinib, including ongoing Phase 3 trials for T-cell lymphoma and advancements in atopic dermatitis studies. The company has ...

Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from ...

SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a ...

CORVUS PHARMACEUTICALS ($CRVS) posted quarterly earnings results on Tuesday, March 25th. The company reported earnings of -$0.18 per share, missing estimates of -$0. ...

(RTTNews) - Corvus Pharmaceuticals, Inc.(CRVS), a clinical-stage biopharmaceutical company, Thursday reported positive data from its Phase 1/1b study of soquelitinib for the treatment of patients ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations ...

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek ...